Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 30, 2024 2:17pm

117 Views

Post# 35961173

RE:RE:RE:RE:Pfizer

For PADCEV and our related ADC technology, we own, co-own or have licensed rights to twelve patents in the United States and Europe that will expire between 2022 and 2031. Of these patents, we own or co-own ten patents and have licensed rights to two patents.

For PADCEV and Pfizer's now owned Seagen acquired related ADC technology, Pfizer now owns, co-owns or has licensed rights to twelve patents in the United States and Europe that will expire between 2022 and 2031. Of these patents, Pfizer/Seagen owns or co-owns ten patents and have licensed rights to two patents.

https://www.sec.gov/Archives/edgar/data/1060736/000106073620000006/a10k2019.htm

Consequently, Pfizer's acquisition of ONCY's biologic pelareorep would provide Pfizer an additional 13 years of market exclusivity, pursuant to the IRA and from the time of approval, should Pfizer gain approval for the triplet combination of pelareorep with the doublet combination of Padcev + keytruda, which both face imminent patent expiration.

As a biologic pelareorep would be a candidate for IRA 13 year market exclusivity in this new single indication for pelareorep of Advanced/Metastatic Bladder Cancer, in combination with Pfizer/Seagen's Padcev + Merck's Keytruda.

Seagen was formely known as Seattle Genetics.

https://en.wikipedia.org/wiki/Seagen

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023